(Jakarta, 28 December 2023) — PT Revass Utama Medika announced that it has now made a management change following the acquisition of an 84% stake by Orbusneich Medical Ltd, a major global medical device manufacturer specializing in interventional devices for percutaneous coronary intervention procedures (PCI) and percutaneous transluminal angioplasty (PTA) headquartered in Hong Kong. This strategic step was signed on November 27, 2023, as the company’s solution to increase the need for health services in Indonesia.
Under the terms of the acquisition agreement, PT Revass will become an indirect non-wholly-owned subsidiary of the Group and its financial results will be consolidated into the Group’s financial statements. PT Revass Utama Medika will continue to operate as an independent entity, PT Revass Utama Medika will continue to operate as an independent entity, which will leverage its resources, expertise, and network to market the best quality medical device products.
Mr. Andriatno Martono, President Director of PT Revass stated, “We are honored to reach a sale and purchase agreement with OrbusNeich, the world’s leading manufacturer of PCI and PTA interventional devices. Both OrbusNeich and PT Revass are committed to providing patients with high-quality medical equipment and treatments. Under the leadership of OrbusNeich, which has rich marketing experience in the international market and high-quality and innovative products, we will be able to introduce more high-quality vascular interventional medical devices to the Indonesian market and benefit more patients there.”
After the acquisition of 84% of the shares that have taken place, PT Revass is optimistic about the company’s business development in the future. We believe this new phase will bring fruitful opportunities to all parties involved. Our goal is to drive a seamless transition that upholds the values and standards we share in the healthcare industry in Indonesia. PT Revass has been involved in the sale and distribution of medical devices in Indonesia for more than 10 years. After years of hard work, it has established a strong sales network in the country, covering more than 200 cardiac catheterization laboratories, and is well-known in the medical industry.